For the first time in nearly 20 years, U.S. regulators have approved a new treatment for Alzheimer's disease. An advisory committee said there isn't enough evidence to show it works, and it will carry a hefty price tag of $56,000 a year. Dr Jeffrey Burns, the co-director of the Alzheimer's Disease Center at the University of Kansas, shared his insights. Watch the video for more on Alzheimer's and the new treatment, Aduhelm.
Copyright © 2020 CGTN. Beijing ICP prepared NO.16065310-3